We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

150 hedge funds and large institutions have $318M invested in PDL BioPharma, Inc. in 2019 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 33 increasing their positions, 63 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

206% more call options, than puts

Call options by funds: $459K | Put options by funds: $150K

63% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 16

49% more capital invested

Capital invested by funds: $214M → $318M (+$104M)

7% more funds holding

Funds holding: 140 → 150 (+10)

48% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 63

Holders
150
Holders Change
+10
Holders Change %
+7.14%
% of All Funds
2.96%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
26
Increased
33
Reduced
63
Closed
16
Calls
$459K
Puts
$150K
Net Calls
+$309K
Net Calls Change
+$165K

Top Buyers

1
ECM
Engine Capital Management
New York
+$18M
2
VLKIM
Van Lanschot Kempen Investment Management
Netherlands
+$4.53M
3
NM
Newtyn Management
New York
+$4.35M
4
AA
Ancora Advisors
Ohio
+$3.81M
5
CCM
Context Capital Management
California
+$2.07M

Top Sellers

1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$7.13M
2
Morgan Stanley
Morgan Stanley
New York
-$3.85M
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.47M
4
UBS Group
UBS Group
Switzerland
-$3.45M
5
BCM
Bridgeway Capital Management
Texas
-$2.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
26
Context Capital Management
California
$2.32M +$2.07M +713,782 New
Millennium Management
27
Millennium Management
New York
$2.24M +$1.28M +442,251 +178%
RC
28
RBF Capital
California
$1.95M +$89.1K +30,677 +5%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.81M -$99.8K -34,381 -6%
PPA
30
Parametric Portfolio Associates
Washington
$1.78M -$346K -119,124 -18%
WFI
31
West Family Investments
California
$1.75M – – –
Federated Hermes
32
Federated Hermes
Pennsylvania
$1.74M -$226K -77,984 -13%
N
33
Nuveen
North Carolina
$1.7M -$4.78K -1,647 -0.3%
Wells Fargo
34
Wells Fargo
California
$1.48M -$686K -236,234 -34%
Goldman Sachs
35
Goldman Sachs
New York
$1.46M -$1.51M -520,353 -54%
Axa
36
Axa
France
$1.05M – – –
Thrivent Financial for Lutherans
37
Thrivent Financial for Lutherans
Minnesota
$974K +$871K +300,000 New
Morgan Stanley
38
Morgan Stanley
New York
$952K -$3.85M -1,327,266 -82%
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$951K -$46.7K -16,100 -5%
AllianceBernstein
40
AllianceBernstein
Tennessee
$903K – – –
Deutsche Bank
41
Deutsche Bank
Germany
$870K +$302K +104,132 +63%
OAM
42
Oxford Asset Management
United Kingdom
$868K -$556K -191,599 -42%
CANY
43
Caxton Associates (New York)
New York
$852K +$541K +186,488 +245%
DCM
44
Dupont Capital Management
Delaware
$773K -$120K -41,378 -15%
AA
45
ALPS Advisors
Colorado
$752K +$12K +4,118 +2%
FM
46
Fondren Management
Texas
$730K +$653K +225,000 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$722K -$11.9K -4,100 -2%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$686K -$685 -236 -0.1%
AWW
49
Alan W. Weber
$650K – – –
SO
50
STRS Ohio
Ohio
$646K -$186K -63,900 -24%
1
2
3 4 5

PDLI Hedge Fund Activity: Q4 2019 in Review

150 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2019, worth a combined $318M — up 49% from $214M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new PDLI positions and 16 closed out — a net gain of 10 holders — while 33 added to existing stakes and 63 trimmed.

The largest buyer was Engine Capital Management, opening a new position worth an estimated $18M. The largest seller was Royal Bank of Canada, cutting an estimated $7.13M.

  • 150 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2019, up from 140 in Q3 2019.
  • Funds reported $318M of PDL BioPharma, Inc. stock for Q4 2019, up 49% quarter-over-quarter.
  • 26 funds opened new PDL BioPharma, Inc. positions in Q4 2019 and 16 closed out, a net change of +10 holders.
  • The largest PDL BioPharma, Inc. buyer in Q4 2019 was Engine Capital Management, an estimated $18M added.
  • The largest PDL BioPharma, Inc. seller in Q4 2019 was Royal Bank of Canada, an estimated $7.13M sold.

Based on aggregated 13F filings for Q4 2019.